AMPH:NSD-Amphastar Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 21.09

Change

+0.22 (+1.05)%

Market Cap

USD 0.98B

Volume

0.20M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Amphastar Pharmaceuticals Inc (AMPH) Stock Analysis:
Based on the Amphastar Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Amphastar Pharmaceuticals Inc is not available over the next 12 months. Amphastar Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Amphastar Pharmaceuticals Inc is Bullish , which is based on 8 positive signals and 3 negative signals. At the last closing, Amphastar Pharmaceuticals Inc’s stock price was USD 21.09. Amphastar Pharmaceuticals Inc’s stock price has changed by +1.53 % over the past week, +1.01 % over the past month and +12.12 % over the last year.

About

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pha ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

+1.56 (+1.93%)

USD7.56B 17.76 37.27
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
TLRY Tilray Inc

+0.29 (+3.17%)

USD4.15B N/A N/A
CGC Canopy Growth Corporation

+0.49 (+4.83%)

USD3.95B N/A N/A
ITCI Intra-Cellular Therapies Inc

+2.51 (+7.13%)

USD2.96B N/A N/A
PCRX Pacira BioSciences Inc

+2.70 (+4.99%)

USD2.34B 39.87 18.10
IRWD Ironwood Pharmaceuticals Inc

+0.25 (+2.23%)

USD1.80B 3.45 7.33
CRON Cronos Group Inc

+0.19 (+4.40%)

USD1.66B 37.00 N/A

ETFs Containing AMPH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.87% 68% D+ 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.87% 68% D+ 51% F
Trailing 12 Months  
Capital Gain 12.12% 69% D+ 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.12% 69% D+ 55% F
Trailing 5 Years  
Capital Gain 5.66% 71% C- 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.66% 71% C- 32% F
Average Annual (5 Year Horizon)  
Capital Gain 4.60% 57% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.60% 57% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 15.41% 98% A+ 83% B
Risk Adjusted Return 29.82% 71% C- 43% F
Market Capitalization 0.98B 81% B- 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 28.91 41% F 31% F
Price/Book Ratio 2.27 55% F 51% F
Price / Cash Flow Ratio 17.05 9% F 24% F
EV/EBITDA 12.41 53% F 52% F
Management Effectiveness  
Return on Equity 8.57% 87% B+ 64% D
Return on Invested Capital 1.69% 80% B- 57% F
Return on Assets 5.28% 88% B+ 80% B-
Debt to Equity Ratio 8.50% 67% D+ 73% C
Technical Ratios  
Short Ratio 11.63 12% F 7% F
Short Percent 5.09% 56% F 32% F
Beta 0.67 79% C+ 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector